Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
This study is conducted in two phases. The first phase of the study will assess the safety, tolerability and reactivity to the COVID-19 vaccine (ChulaCov19 messenger ribonucleic acid) administered at various doses through the muscles among healthy adults and the elderlies (age 65-75 years) (total 96 participants). Phase 2 will proceed dependent upon the results from phase 1 of the study. The second phase of the study will assess whether the vaccine can activate the immune system or not (total 600 participants) among healthy adults and the elderlies.
Description: Frequency of Adverse Events
Measure: Frequency of Adverse Events Time: up to Day 50Description: Grade of Adverse Events
Measure: Grade of Adverse Events Time: up to Day 50Description: Frequency of solicited reportable local Adverse Events: pain at the injection site, redness, swelling, erythema
Measure: Frequency of solicited reportable local Adverse Events Time: during a 7-day follow-up period post each vaccinationDescription: Grade of solicited reportable local Adverse Events: pain at the injection site, redness, swelling, erythema
Measure: Grade of solicited reportable local Adverse Events Time: during a 7-day follow-up period post each vaccinationDescription: Frequency of solicited reportable systemic Adverse Events: fever, fatigue, chills, headache, myalgias, arthralgias, vomiting, diarrhoea, new or worsened muscle pain (myalgias), and new or worsened joint pain (arthralgias).
Measure: Frequency of solicited reportable systemic Adverse Events Time: during a 7-day follow-up period post each vaccinationDescription: Grade of of solicited reportable systemic Adverse Events: fever, fatigue, chills, headache, myalgias, arthralgias, vomiting, diarrhoea, new or worsened muscle pain (myalgias), and new or worsened joint pain (arthralgias).
Measure: Grade of of solicited reportable systemic Adverse Events Time: during a 7-day follow-up period post each vaccinationDescription: Frequency of Serious Adverse Events
Measure: Frequency of Serious Adverse Events Time: up to Day 387Description: Frequency of Medically-Attended Adverse Events
Measure: Frequency of Medically-Attended Adverse Events Time: up to Day 387Description: Frequency of New-Onset Chronic Medical Conditions
Measure: Frequency of New-Onset Chronic Medical Conditions Time: up to Day 387Description: degrees Celsius
Measure: Measurement of body temperature Time: Day -42, Day 1, Day 2, Day 8, Day 22, Day 29, Day 50, Day 112, Day 202, and Day 387Description: per minute
Measure: measurement of respiratory rate Time: Day -42, Day 1, Day 2, Day 8, Day 22, Day 29, Day 50, Day 112, Day 202, and Day 387Description: beats per minute (BPM)
Measure: measurement of pulse rate Time: Day -42, Day 1, Day 2, Day 8, Day 22, Day 29, Day 50, Day 112, Day 202, and Day 387Description: millimeter of mercury (mmHg)
Measure: measurement of systolic blood pressure (SBP) Time: Day -42, Day 1, Day 2, Day 8, Day 22, Day 29, Day 50, Day 112, Day 202, and Day 387Description: millimeter of mercury (mmHg)
Measure: measurement of diastolic blood pressure (DBP) Time: Day -42, Day 1, Day 2, Day 8, Day 22, Day 29, Day 50, Day 112, Day 202, and Day 387Description: assess if there are any symptoms at the head
Measure: assess if there are any symptoms at the head Time: Day -42, Day 1, Day 8, Day 22, Day 29, Day 50, Day 112, Day 202, and Day 387Description: assess if there are any symptoms at the ears
Measure: assess if there are any symptoms at the ears Time: Day -42, Day 1, Day 8, Day 22, Day 29, Day 50, Day 112, Day 202, and Day 387Description: assess if there are any symptoms at the nose
Measure: assess if there are any symptoms at the nose Time: Day -42, Day 1, Day 8, Day 22, Day 29, Day 50, Day 112, Day 202, and Day 387Description: assess if there are any symptoms at the throat
Measure: assess if there are any symptoms at the throat Time: Day -42, Day 1, Day 8, Day 22, Day 29, Day 50, Day 112, Day 202, and Day 387Description: assess if there are any symptoms at the lungs
Measure: assess if there are any symptoms at the lungs Time: Day -42, Day 1, Day 8, Day 22, Day 29, Day 50, Day 112, Day 202, and Day 387Description: assess if there are any symptoms at the lymph nodes
Measure: assess if there are any symptoms at the lymph nodes Time: Day -42, Day 1, Day 8, Day 22, Day 29, Day 50, Day 112, Day 202, and Day 387Description: assess if there are any symptoms at the heart
Measure: assess if there are any symptoms at the heart Time: Day -42, Day 1, Day 8, Day 22, Day 29, Day 50, Day 112, Day 202, and Day 387Description: assess if there are any symptoms at the abdomen
Measure: assess if there are any symptoms at the abdomen Time: Day -42, Day 1, Day 8, Day 22, Day 29, Day 50, Day 112, Day 202, and Day 387Description: assess if there are any symptoms at the skin
Measure: assess if there are any symptoms at the skin Time: Day -42, Day 1, Day 8, Day 22, Day 29, Day 50, Day 112, Day 202, and Day 387Description: g/dl
Measure: Measurement of haemoglobin (Hb) Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: 10^6 cells/ul
Measure: Measurement of red blood cell (RBC) Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: 10^3 cells/ul
Measure: Measurement of white blood cells (WBC) Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: percentage
Measure: Assess the percentage of neutrophil Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: 10^3 cells/ul
Measure: Assess the number of neutrophil Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: percentage
Measure: Assess the percentage of lymphocytes Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: 10^3 cells/ul
Measure: Assess the number of lymphocytes Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: percentage
Measure: Assess the percentage of eosinophil Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: 10^3 cells/ul
Measure: Assess the number of eosinophil Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: Percentage
Measure: Assess the percentage of basophil Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: 10^3 cells/ul
Measure: Assess the number of basophil Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: percentage
Measure: Assess the percentage of monocytes Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: 10^3 cells/ul
Measure: Assess the number of monocytes Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: 10^3 cells/ul
Measure: Measurement of platelet Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: mmol/l
Measure: Measurement of sodium Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: mmol/l
Measure: Measurement of potassium Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: mmol/l
Measure: Measurement of chloride Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: mmol/l
Measure: Measurement of bicarbonate Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: mg/dL
Measure: Measurement of blood urea nitrogen (BUN) Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: mg/dl
Measure: Measurement of creatinine Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: g/dL
Measure: Assess total protein Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: g/dL
Measure: Measurement of albumin Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: unit/Liter (U/L)
Measure: Measurement of lipase Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: mmol/L
Measure: Measurement of phosphorus Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: U/L
Measure: Measurement of gamma-glutamyl transferase (GGT) Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: mg/dL
Measure: Measurement of glucose Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: U/L
Measure: Measurement of creatinine phosphokinase (CPK) Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: mmol/L
Measure: Measurement of calcium Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: mg/dL
Measure: Measurement of uric acid Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: mg/dL
Measure: Measurement of C-reactive protein (CRP) Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: U/L
Measure: Measurement of alanine transaminase (ALT) Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: U/L
Measure: Measurement of aspartate transaminase (AST) Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: U/L
Measure: Measurement of alkaline phosphatase (ALP) Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: mg/dL
Measure: Assess total bilirubin Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: ml/min/1-73m^2
Measure: Assess estimated glomerular filtration rate (eGFR) Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: second
Measure: Measurement of prothrombin time (PT) Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: second
Measure: Measurement of partial thromboplastin time (PTT) Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: ratio
Measure: Measurement of international normalized ratio (INR) Time: Day -42, Day 1,Day 8, Day 22, Day 29, Day 50Description: Geometric mean titers (GMT) in SARS-CoV-2-specific serum neutralising antibody levels
Measure: Geometric mean titers (GMT) in SARS-CoV-2-specific serum neutralising antibody levels Time: at Day 29 (7 days after the second dose)Description: Proportion of participants who achieved a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2-specific serum neutralising antibody levels
Measure: Proportion of participants who achieved a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2-specific serum neutralising antibody levels Time: At Day 29Description: Geometric mean fold rises (GMFR) in SARS-CoV-2-specific serum neutralising titers
Measure: Geometric mean fold rises (GMFR) in SARS-CoV-2-specific serum neutralising titers Time: from baseline to Day 29Description: Geometric mean titers (GMT) in SARS-CoV-2 surrogate viral neutralising antibody levels
Measure: Geometric mean titers (GMT) in SARS-CoV-2 surrogate viral neutralising antibody levels Time: at Day 29Description: Proportion of participants who achieved a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 surrogate viral neutralising antibody levels
Measure: Proportion of participants who achieved a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2 surrogate viral neutralising antibody levels Time: at Day 29Description: Geometric mean fold rises (GMFR) in SARS-CoV-2 surrogate viral neutralising antibody titers
Measure: Geometric mean fold rises (GMFR) in SARS-CoV-2 surrogate viral neutralising antibody titers Time: from baseline to Day 29Description: Geometric mean titers (GMT) of SARS-Cov2-spike protein-binding IgG antibody
Measure: Geometric mean titers (GMT) of SARS-Cov2-spike protein-binding IgG antibody Time: at Day 29Description: Proportion of participants who seroconverted: achieving a greater than or equal to 4-fold rise in SARS-Cov2-spike protein-binding IgG antibody
Measure: Proportion of participants who seroconverted: achieving a greater than or equal to 4-fold rise in SARS-Cov2-spike protein-binding IgG antibody Time: from baseline to Day 29Description: Geometric mean fold rises (GMFR) in SARS-Cov2-spike protein-binding IgG antibody
Measure: Geometric mean fold rises (GMFR) in SARS-Cov2-spike protein-binding IgG antibody Time: from baseline to Day 29Description: Percentage of participants who have positive specific CD4 T-cell IFNγ ELISpot responses
Measure: Percentage of participants who have positive specific CD4 T-cell IFNγ ELISpot responses Time: Day 29Description: Percentage of participants who have positive specific CD8 T-cell IFNγ ELISpot responses
Measure: Percentage of participants who have positive specific CD8 T-cell IFNγ ELISpot responses Time: Day 29Description: Median number of spot-forming cells (SFC) per 1 million PBMCs
Measure: Median number of spot-forming cells (SFC) per 1 million PBMCs Time: Day 29Description: Percentage of participants who shows positive specific Th1 responses
Measure: Percentage of participants who shows positive specific Th1 responses Time: Day 29Description: Percentage of participants who shows positive specific Th2 responses
Measure: Percentage of participants who shows positive specific Th2 responses Time: Day 29Description: Median percentage specific Th1 responses
Measure: Median percentage specific Th1 responses Time: Day 29Description: Median percentage specific Th2 responses
Measure: Median percentage specific Th2 responses Time: Day 29Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports